Toggle light / dark theme

Alternative Cancer Treatments Brought to Legitimacy at Scientific Forum in San Diego

The world recently acknowledged the power of alternative cancer treatments by awarding the 2018 Nobel Prize in Medicine to Dr. James P. Allison and Dr. Tasuku Honjo for their work in immunotherapy. More specifically on checkpoint inhibitor therapies.

Until recently many in the scientific community had dismissed immunotherapy as a viable cancer treatment. Nevertheless, Allison and Honjo persevered and their breakthrough has allowed for the classification of new drugs and treatments that may help patients have run out of options.

Ironically, while many in the mainstream are barely learning of immunotherapy, a hospital in Mexico, CHIPSA Hospital, has been working with these treatments for over 38 year and often under fire from public ridicule that their treatments are strange and ineffective.

Read more

The Future of Pensions

Nicola Bagalà and Michael Nuschke take a look at the future of pensions and how the possible defeat of age-related diseases will affect them.


If you work in social security, it’s possible that your nightmares are full of undying elderly people who keep knocking on your door for pensions that you have no way of paying out. Tossing and turning in your bed, you beg for mercy, explaining that there’s just too many old people who need pensions and not enough young people who could cover for it with their contributions; the money’s just not there to sustain a social security system that, when it was conceived in the mid-1930s, didn’t expect that many people would ever make it into their 80s and 90s. Your oneiric persecutors won’t listen: they gave the country the best years of their lives, and now it’s time for the country to pay them their due.

When you wake up, you’re relieved to realize that there can’t be any such thing as people who have ever-worsening degenerative diseases yet never die from them, but that doesn’t make your problem all that better; you still have quite a few old people, living longer than the pension system had anticipated, to pay pensions to, and the bad news is that in as little as about 30 years, the number of 65+ people worldwide will skyrocket to around 2.1 billion, growing faster than all younger groups put together [1]. Where in the world is your institution going to find the budget?

Read more

How whales defy the cancer odds: Good genes

But they don’t. Instead, they are less likely to develop or die of this enigmatic disease. The same is true of elephants and dinosaurs’ living relatives, birds. Marc Tollis, an assistant professor in the School of Informatics, Computing, and Cyber Systems at Northern Arizona University, wants to know why.

Tollis led a team of scientists from Arizona State University, the University of Groningen in the Netherlands, the Center for Coastal Studies in Massachusetts and nine other institutions worldwide to study potential cancer suppression mechanisms in cetaceans, the mammalian group that includes whales, dolphins and porpoises. Their findings, which picked apart the genome of the humpback whale, as well as the genomes of nine other cetaceans, in order to determine how their cancer defenses are so effective, were published today in Molecular Biology and Evolution.

The study is the first major contribution from the newly formed Arizona Cancer and Evolution Center or ACE, directed by Carlo Maley under an $8.5 million award from the National Cancer Institute. Maley, an evolutionary biologist, is a researcher at ASU’s Biodesign Virginia G. Piper Center for Personalized Diagnostics and professor in the School of Life Sciences. He is a senior co-author of the new study.


Europe abandons plans for ‘flagship’ billion-euro research projects

The consortium, called LifeTime, aims to use three emerging technologies—machine learning, the study of single cells, and lab-grown organlike tissues called organoids—to map how human cells change over time and develop diseases. It is one of six candidates in the latest round of ambitious proposals for European flagships, billion-euro research projects intended to run for 10 years. There is just one snag: The European Commission has decided that it won’t launch any of them.


Six candidate research proposals lost in limbo.

Read more